证券日报网讯 11月20日晚间，博拓生物发布公告称，2025年11月19日，于秀萍女士通过集中竞价交易 （含盘后固定价格交易，下同）和大宗交易的方式合计减持公司股份3，636，600股，占公司当前总股 本的2.44%。于秀萍女士及其一致行动人合计持有的公司股份数量由86，688，000股减少至83，051， 400股，占公司总股本的比例由58.05%减少至55.61%，权益变动触及1%的整数倍。 （文章来源：证券日报） ...

证券代码：688767 证券简称：博拓生物 公告编号：2025-043 | 本公司董事会及全体董事保证公告内容与信息披露义务人提供的信息一致。 | | | | | --- | --- | --- | --- | | 权益变动方向 | 比例增加□ | | 比例减少□√ | | 权益变动前合计比例 | 58.05% | | | | 权益变动后合计比例 | 55.61% | | | | 本次变动是否违反已作出的承 诺、意向、计划 | 是□ | 否□√ | | | 是否触发强制要约收购义务 | 是□ | 否□√ | | 一、 信息披露义务人及其一致行动人的基本信息 1.身份类别 | | □√ 控股股东/实际控制人及其一致行动人 | | --- | --- | | | □其他 5%以上大股东及其一致行动人 | | 投资者及其一致行动人的身份 | □合并口径第一大股东及其一致行动人（仅适用 | | | 于无控股股东、实际控制人） | | | □其他______________（请注明） | 2.信息披露义务人信息 杭州博拓生物科技股份有限公司关于实际控制人及 其一致行动人权益变动触及 1%刻度的提示性公告 杭州博拓生物科 ...

格隆汇11月20日丨博拓生物(688767.SH)公布，2025年11月19日，于秀萍女士通过集中竞价交易(含盘后 固定价格交易，下同)和大宗交易的方式合计减持公司股份363.66万股，占公司当前总股本的2.44%。于 秀萍女士及其一致行动人合计持有的公司股份数量由8668.8万股减少至8305.14万股,占公司总股本的比 例由58.05%减少至55.61%，权益变动触及1%的整数倍。 ...

博拓生物公告，公司实际控制人于秀萍女士通过集中竞价交易和大宗交易方式合计减持公司股份363.66 万股，占公司当前总股本的2.44%。于秀萍及其一致行动人合计持有的公司股份数量由8668.8万股减少 至8305.14万股，占公司总股本的比例由58.05%减少至55.61%。此次权益变动不违反已作出的承诺、意 向、计划，不触发强制要约收购义务。 ...

格隆汇11月20日丨博拓生物(688767.SH)公布，2025年11月19日，于秀萍女士通过集中竞价交易(含盘后 固定价格交易，下同)和大宗交易的方式合计减持公司股份363.66万股，占公司当前总股本的2.44%。于 秀萍女士及其一致行动人合计持有的公司股份数量由8668.8万股减少至8305.14万股,占公司总股本的比 例由58.05%减少至55.61%，权益变动触及1%的整数倍。 ...

| 成交量 | 成交金额 | 成交价 | 相对当日收盘 | | | | --- | --- | --- | --- | --- | --- | | （万 | （万元） | 格 | 折溢价（%） | 买方营业部 | 卖方营业部 | | 股） | | （元） | | | | | 75.94 | 2927.49 | 38.55 | -7.71 | 机构专用 | 国泰海通证券股份有限公司 | | | | | | | 杭州文一西路证券营业部 | | 74.67 | 2878.34 | 38.55 | -7.71 | 机构专用 | 国泰海通证券股份有限公司 | | | | | | | 杭州文一西路证券营业部 | | 74.67 | 2878.34 | 38.55 | -7.71 | 财通证券股份有限公司杭 | 国泰海通证券股份有限公司 | | | | | | 州文二西路证券营业部 | 杭州文一西路证券营业部 | | 34.19 | 1318.02 | 38.55 | -7.71 | 机构专用 | 国泰海通证券股份有限公司 | | | | | | | 杭州文一西路证券营业部 | | 26.70 | 1029.29 | 38 ...

| 交易日期 | 证券简称 | 证券代码 | 成交价(元) 成交金额(万元) 成交量(*) 买入营业部 | | | 卖出营业部 | 是否为专场 | | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-11-19 | 博拓生物 | 688767 38.55 | 1318.02 | 34.19 | 机构专用 | 日常日报 | 整 | | 2025-11-19 | 博拓生物 | 688767 38.55 | 1029.29 | 26.7 | 机构专用 | | KI | | 2025-11-19 | 博拓生物 | 688767 38.55 | 481.88 | 12.5 | 机构专用 | 最大 | る | | 大宗交易信息 | | | | | | | | | 股票基金信息 | | | | | | | | | 交易日期 | 证券简称 | 证券代码 | 成交价(元) 成交金额(万元) 成交量(*) 买入营业部 | | | 卖出营业部 | 是否为专场 | | 2025-11-19 | 博拓生物 | 688767 38.55 | 2927.49 | 75.94 | ...

Market Overview - The Shanghai Composite Index closed at 3949.83 points, with a decline of 0.56% [1] - The total trading volume of A-shares reached 1,296.161 billion yuan [1] Technical Analysis - A total of 112 A-shares experienced a death cross, where the 5-day moving average fell below the 10-day moving average [1] - Notable stocks with significant distance between their 5-day and 10-day moving averages include: - Shanshui Bide (300844) with a distance of -1.40% - Yingboer (300681) with a distance of -1.28% - Yake Technology (002409) with a distance of -1.06% [1] Individual Stock Performance - Shanshui Bide (300844) saw a decline of 6.62% with a trading turnover rate of 3.31% [1] - Yingboer (300681) decreased by 2.30% with a turnover rate of 2.45% [1] - Yake Technology (002409) fell by 0.20% with a turnover rate of 2.33% [1] - Other notable declines include: - Bohai Automobile (600960) down by 3.53% - Western Gold (601069) down by 2.80% [1] Additional Stock Movements - Stocks such as Muyu (002714) and Qinglong (002457) showed slight increases of 0.80% and -3.28% respectively [2] - The stock performance of various companies indicates a mixed sentiment in the market, with several stocks experiencing declines while a few managed to gain [2]

Core Viewpoint - The fentanyl concept sector experienced a decline of 1.68% as of the market close on November 17, with companies such as Enhua Pharmaceutical, Renfu Pharmaceutical, and Lingrui Pharmaceutical leading the losses [1] Market Performance - The fentanyl concept sector ranked among the top decliners, with a notable drop compared to other sectors such as military restructuring, which increased by 4.72% [1] - Other sectors that saw declines include cell immunotherapy (-1.87%), weight loss drugs (-1.87%), and innovative drugs (-1.72%) [1] Capital Flow - The fentanyl concept sector saw a net outflow of 153 million yuan, with five stocks experiencing significant capital outflows [1] - Renfu Pharmaceutical had the highest net outflow at 83.49 million yuan, followed by Lingrui Pharmaceutical (36.78 million yuan) and Enhua Pharmaceutical (24.86 million yuan) [1] - Conversely, the stocks with net inflows included Guoyao Co., Botao Bio, and Dongfang Bio, with net inflows of 2.91 million yuan, 849,400 yuan, and 285,900 yuan respectively [1] Individual Stock Performance - The top stocks in the fentanyl concept sector by net outflow include: - Renfu Pharmaceutical: -2.36% with a net outflow of 83.49 million yuan - Lingrui Pharmaceutical: -2.12% with a net outflow of 36.78 million yuan - Enhua Pharmaceutical: -2.93% with a net outflow of 24.86 million yuan [1] - In contrast, Guoyao Co. and Botao Bio showed slight positive movements with net inflows [1]

Core Insights - The fentanyl concept index declined by 0.31%, ranking among the top decliners in the concept sector, with notable declines in stocks such as Botao Bio, Oriental Bio, and Lingrui Pharmaceutical [1][2] - Conversely, three stocks within the sector saw price increases, with Renfu Pharmaceutical, Enhua Pharmaceutical, and China National Pharmaceutical Modern rising by 1.02%, 0.52%, and 0.19% respectively [1][2] Market Performance - The fentanyl concept sector experienced a net inflow of 0.22 billion yuan, despite five stocks facing net outflows, with Oriental Bio leading the outflow at 14.71 million yuan [2] - Other stocks with significant net outflows included China National Pharmaceutical Modern (10.27 million yuan), Wanfu Bio (7.15 million yuan), and Botao Bio (3.49 million yuan) [2] Stock Movements - The top gainers in the fentanyl concept included Renfu Pharmaceutical, China National Pharmaceutical, and Lingrui Pharmaceutical, with net inflows of 42.39 million yuan, 15.59 million yuan, and 2.54 million yuan respectively [2] - The stock performance of Oriental Bio showed a decline of 0.97% with a turnover rate of 1.75%, while Renfu Pharmaceutical had a gain of 1.02% with a turnover rate of 1.51% [2]